Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT(1A) receptor antagonist, WAY-100635

Behavioural Pharmacology

Volumn 8, Issue 6-7, 1997, Pages 585-606

  Mitchell, P J ^a   Redfern, P H ^a  

^a University of Bath   (United Kingdom)

Author keywords

5 Hydroxytryptamine(1A) receptor antagonist; Aggressive behaviour; Antidepressant augmentation; Antidepressants; Head body shake behaviour; Rat; Resident intruder; Sexual behaviour

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; SEROTONIN 1A ANTAGONIST; VENLAFAXINE;

AGGRESSION; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG POTENTIATION; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030830398     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199711000-00016     Document Type: Article

References (81)

1. Adell A and Artigas F (1991) Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphé nuclei and frontal cortex. An in-vivo brain microdialysis study. Naunyn-Schmiedeberg's Archives of Pharmacology, 343, 237-244.
2. Ahlenius S and Larsson K (1988) Effects of the putative 5-HT agonist 5-OH-DPAC on male rat sexual behaviour: a comparison with effects produced by 8-OH-DPAT and buspirone. Journal of Psychopharmacology, 2, 47-53.
3. Artigas F (1993) 5-HT and antidepressants: new views from microdialysis studies. Trends in Pharmacological Sciences, 14, 262.
4. Artigas F, Perez V and Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry, 51, 248-251.
5. 1B receptors. Neuropharmacology, 35, 213-222.
6. Bakish D (1991) Fluoxetine potentiation by buspirone: three case histories. Canadian Journal of Psychiatry, 36, 749-750.
7. Baldwin D, Thomas S and Birtwistle J (1997) Effects of antidepressant drugs on sexual function. International Journal of Psychiatry in Clinical Practice, 1, 47-58.
8. Bel N and Artigas F (1993) Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphé nuclei. Synapse, 15, 243-245.
9. 1B characterizing agents in the mouse elevated plus-maze. Life Sciences, 47, 195-203.
10. 1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or anti-depressants. Psychopharmacology, 105, 219-224.
11. Berman RM, Darnell AM, Miller HL, Anand A and Charney DS (1997) Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. American Journal of Psychiatry, 154, 37-43.
12. Blier P and Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology, 15, 217-222.
13. Blier P and Bergeron R (1996) Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: Preliminary findings. International Clinical Psychopharmacology, 11, 37-44.
14. Blier P and de Montigny C (1994) Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences, 15, 220-226.
15. Blier P, de Montigny C and Chaput Y (1990) A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Journal of Clinical Psychiatry, 51, 14S-20S.
16. Bosker FJ, Donker MG, Klompmakers AA, Kurata K and Westenberg HGM (1994) 5-Hydroxytryptamine release in dorsal hippocampus of freely moving rats: modulation by pindolol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18, 765-778.
17. Carlsson A and Lindqvist M (1978) Effects of antidepressant agents on the synthesis of brain monoamines. Journal of Neural Transmission, 43, 73-91.
18. Ceulemans D, Hoppenbrouwers M, Gelders Y and Reyntjens A (1985) The influence of ritanserin, a serotonergic antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry, 18, 303-305.
19. Chaput Y, de Montigny C and Blier P (1986) Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 333, 342-348.
20. Charney D, Woods S, Goodman W and Heninger G (1987) Serotonin function in anxiety: II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology, 92, 14-24.
21. 1A ligands on the agonistic behaviour of rats. Journal of Psychopharmacology Abstract Book BAP/ISBP Meeting, 8, Abstract 24.
22. 1A receptors. Journal of Psychopharmacology Abstract Book BAP/ISBP Meeting, 8, Abstract 25.
23. Darmani N, Shaddy J and Gerdes C (1996) Differential ontogeny of 3 DOI-induced behaviours in mice. Physiology and Behaviour, 60, 1495-1500.
24. 1D autoreceptors. British Journal of Pharmacology, 114, 1107-1109.
25. 1B antagonists. Neuroscience Letters, 188, 41-44.
26. 1A receptors. Neurochemical Research, 21, 557-562.
27. 2A receptors are active under physiological conditions. Psychopharmacology, 128, 198-205.
28. 1B agonists on masculine sexual behaviour: physiological and pharmacological implications. Journal of Neural Transmission - General Section, 85, 95-107.
29. Fone K, Robinson A and Marsden C (1991) Characterization of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats. British Journal of Pharmacology, 103, 1547-1555.
30. Fornal CA and Jacobs BL (1988) Physiological and behavioural correlates of serotonergic single unit activity. In: Neuronal Serotonin (Eds NN Osborne and M Hamon), pp. 305-346. Wiley, Chichester.
31. 1A receptor antagonist, WAY-100635. European Journal of Pharmacology, 281, 81-88.
32. Fuller RW, Perry KW, HemrickLuecke SK and Engleman E (1996) Serum corticosterone increases reflect enhanced uptake inhibitor-induced elevation of extracellular 5-hydroxytryptamine in rat hypothalamus. Journal of Pharmacy and Pharmacology, 48, 68-70.
33. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. British Journal of Pharmacology, 115, 1064-1070.
34. Germine M, Goddard A, Woods S, Charney D and Heninger G (1992) Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biological Psychiatry, 32, 457-461.
35. 2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. Journal of Medicinal Chemistry, 29, 194-199.
36. Grant EC (1963) An analysis of the social behaviour of the male laboratory rat. Behaviour, 21, 260-281.
37. Griebel G, Blanchard DC, Agnes RS and Blanchard RJ (1995a) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology, 120, 57-66.
38. 2A antagonist pirenperone. Pharmacology, Biochemistry and Behavior, 51, 235-244.
39. Hajos M, Gartside SE and Sharp T (1995) Inhibition of median and dorsal raphé neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn-Schmiedeberg's Archives of Pharmacology, 351, 624-629.
40. Hewitt KN, Hutchins LJ, Cheetham SC and Jackson HC (1996) Pindolol augments the effects of SSRIs and desipramine in an animal of depression. Journal of Psychopharmacology, 10 (Suppl), Abstract 241.
41. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. Journal of Neurochemistry, 60, 776-779.
42. Hjorth S (1996) (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. European Journal of Pharmacology, 303, 183-186.
43. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. European Journal of Pharmacology, 260, 251-255.
44. 1-adrenoceptors in the inhibition of 5-HT release. I. BMY7378 and prazosin. Neuropharmacology, 34, 615-620.
45. 1 recognition sites. Journal of Receptor Research, 8, 59-81.
46. 3H]imipramine localization and relationship to the serotonin transporter. Journal of Pharmacology and Experimental Therapeutics, 252, 410-418.
47. Invernizzi R, Belli S and Samanin R (1992) Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphé prevents the drug's effect in the frontal cortex. Brain Research, 584, 322-324.
48. 1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacology Biochemistry and Behavior, 54, 143-147.
49. Jacobsen FM (1991) Possible augmentation of antidepressant response by buspirone. Journal of Clinical Psychiatry, 52, 217-220.
50. 3 receptors. Psychopharmacology, 97, 489-495.
51. Jenck F, Moreau JL and Martin JR (1995) Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Research, 57, 181-191.
52. Joffe RT and Schuller DR (1993) An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. Journal of Clinical Psychiatry, 54, 269-271.
53. Kahn R, Welzer S, Van Praag H, Asnis G and Strauman T (1988) Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Research, 25, 101-104.
54. 2C/2B receptor antagonist. British Journal of Pharmacology, 111, 797-802.
55. 2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology, 118, 178-182.
56. Klein E, Zohar J, Geraci M, Murphy D and Uhde T (1991) Anxiogenic effects of meta-CPP in patients with panic disorder - comparison to caffeine's anxiogenic effects. Biological Psychiatry, 30, 973-984.
57. Kreiss DS, Wieland S and Lucki I (1993) The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release. Neuroscience, 52, 295-301.
58. Maj J, Bijak M, Dziedzicka-Wasylewska M, Rogoz R, Rogoz Z, Skuza G and Tokarski T (1996) The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology, 127, 73-82.
59. Meert T and Janssen P (1989) Psychopharmacology of ritanserin: comparison with chlordiazepoxide. Drug Development Research, 18, 119.
60. 1 site. European Journal of Pharmacology, 90, 151-153.
61. Mitchell PJ (1994) Prediction of antidepressant activity from ethological analysis of agonistic behaviour in rats. In: Ethology and Psychopharmacology (Eds SJ Cooper and C Hendrie), pp. 85-109. J. Wiley and Sons Ltd., Chichester.
62. Mitchell PJ and Fletcher A (1993) Venlafaxine exhibits preclinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology, 32, 1001-1009.
63. Mitchell PJ and Forster EA (1992) Gepirone exhibits antidepressant-like activity on the social/agonistic behaviour of resident rats. Journal of Psychopharmacology Abstract Book BAP/ESBP Meeting, Abstract 335.
64. Mitchell PJ and Redfern PH (1992) Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats. Journal of Psychopharmacology, 6, 241-257.
65. Mitchell PJ and Redfern PH (1997) Effects of citalopram and paroxetine on rodent social and agonistic behaviour. Journal of Psychopharmacology, 11 (Suppl), Abstract 161.
66. Mitchell PJ, Fletcher A and Redfern PH (1991) Is antidepressant efficacy revealed by drug-induced changes in rat behaviour exhibited during social interaction? Neuroscience and Biobehavioral Reviews, 15, 539-544.
67. Mos J, Van Logten J, Bloetjes K and Olivier B (1991) The effects of idazoxan and 8-OH-DPAT on sexual behaviour and associated ultrasonic vocalizations in the rat. Neuroscience and Biobehavioral Reviews, 15, 505-510.
68. Nelson D, Thomas D and Johnson A (1989) Pharmacological effects of paroxetine after repeated administration to animals. Acta Psychiatrica Scandinavica, 80, 21.
69. Peroutka SJ and Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science, 210, 88-90.
70. Pigott T, Zohar J, Hill J, Bernstein S, Grover G, ZoharKadouch R and Murphy D (1991) Metergoline blocks the behavioural and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biological Psychiatry, 29, 418-426.
71. Pineyro G, Blier P, Dennis T and de Montigny C (1994) Desensitization of the neuronal 5-HT carrier following its long-term blockade. Journal of Neuroscience, 14, 3036-3047.
72. Porsolt RD, Bertin A and Jalfre M (1977) Behavioural despair in mice: a primary screening test for antidepressants. Archives of International Pharmacodynamics and Therapeutics, 229, 327-336.
73. 2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist. Biochemical Pharmacology, 42, 1099-1105.
74. Rickels K, Amsterdam JD, Clary CPG and Schweizer E (1991) Buspirone in major depression: a controlled study. Journal of Clinical Psychiatry, 52, 34-38.
75. 1A receptors - in-vivo microdialysis and electrophysiological studies in the rat brain. Neuro-psychopharmacology, 15, 349-360.
76. Sharp T, Bramwell SR, Hjorth S and Graham-Smith DG (1989) Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. British Journal of Pharmacology, 98, 989-997.
77. 3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine(mCPP)-induced changes in human volunteers. Biological Psychiatry, 36, 309-316.
78. 2 agonist DOI. Neuroscience Letters, 141, 25-29.
79. Westenberg H and Den Boer J (1994) The neuropharmacology of anxiety: a review on the role of serotonin. In: Handbook of Depression and Anxiety: A Biological Approach (Eds J Den Boer and J Sitsen), pp. 405-446. Marcel Dekker Inc., New York.
80. Wong D and Bymaster F (1981) Subsensitivity of serotonin receptors after long-term treatment of rats with fluoxetine. Research Communications in Chemical Pathology and Pharmacology, 32, 141-151.
81. Zohar J, Muellar E, Insel T, ZoharKadouch R and Murphy D (1987) Serotonergic responsitivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Archives of General Psychiatry, 44, 946-951.